Q1 Earnings Estimate for Surrozen Issued By HC Wainwright

Surrozen, Inc. (NASDAQ:SRZN) – Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for Surrozen in a report issued on Monday, November 10th. HC Wainwright analyst M. Caufield anticipates that the company will earn ($1.20) per share for the quarter. The consensus estimate for Surrozen’s current full-year earnings is ($8.49) per share. HC Wainwright also issued estimates for Surrozen’s Q2 2026 earnings at ($1.17) EPS, Q3 2026 earnings at ($1.18) EPS and Q4 2026 earnings at ($1.18) EPS.

Surrozen (NASDAQ:SRZN) last announced its quarterly earnings results on Friday, November 7th. The company reported ($3.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($2.44). The company had revenue of $0.98 million for the quarter. Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $38.50.

Surrozen Price Performance

Shares of Surrozen stock opened at $12.94 on Tuesday. Surrozen has a fifty-two week low of $5.90 and a fifty-two week high of $18.17. The firm has a market capitalization of $110.90 million, a P/E ratio of -0.58 and a beta of 0.64. The company’s 50 day moving average price is $12.79 and its two-hundred day moving average price is $10.56.

Hedge Funds Weigh In On Surrozen

Several large investors have recently modified their holdings of SRZN. Geode Capital Management LLC grew its stake in shares of Surrozen by 22.6% in the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after purchasing an additional 5,702 shares during the last quarter. Heights Capital Management Inc. bought a new position in Surrozen during the 1st quarter worth $524,000. Armistice Capital LLC acquired a new position in Surrozen during the 2nd quarter worth about $536,000. Adage Capital Partners GP L.L.C. grew its position in shares of Surrozen by 37.1% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 88,653 shares of the company’s stock valued at $1,034,000 after buying an additional 24,000 shares during the last quarter. Finally, Braidwell LP acquired a new stake in shares of Surrozen in the second quarter valued at about $1,252,000. Institutional investors own 66.57% of the company’s stock.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.